Investigational Drug Information for Atiprimod
✉ Email this page to a colleague
What is the drug development status for Atiprimod?
Atiprimod is an investigational drug.
There have been 5 clinical trials for Atiprimod.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2006.
The most common disease conditions in clinical trials are Carcinoma, Neuroendocrine, Carcinoma, and Neoplasms. The leading clinical trial sponsors are Callisto Pharmaceuticals, M.D. Anderson Cancer Center, and [disabled in preview].
Summary for Atiprimod
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,500 |
| WIPO Patent Applications | 741 |
| Japanese Patent Applications | 112 |
| Clinical Trial Progress | Phase 2 (2006-10-01) |
| Vendors | 19 |
Recent Clinical Trials for Atiprimod
| Title | Sponsor | Phase |
|---|---|---|
| Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma | Callisto Pharmaceuticals | Phase 2 |
| Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | Callisto Pharmaceuticals | Phase 2 |
| An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer | Callisto Pharmaceuticals | Phase 1/Phase 2 |
Clinical Trial Summary for Atiprimod
Top disease conditions for Atiprimod
Top clinical trial sponsors for Atiprimod
US Patents for Atiprimod
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
